Skip to content

The Brief
Reports
The Pulse
- NeuroPulse
- OrphanPulse
Topics

NeuroPulse Wk 43: Roche's MS Pill Cut Relapses by 55% and Is Under Priority Review

NeuroPulse Wk 43: Roche’s MS Pill Cut Relapses by 55% and Is Under Priority Review

Athithi Verma October 26, 2026

Fenebrutinib cut relapses by 55% and could become the first pill for primary progressive MS, if its safety holds up.

DealPulse Signal Wk 43: EQT Paid $12.1 Billion for QIAGEN, and Roche Paid $400 Million on a $15.5 Billion ADC Deal

DealPulse Signal Wk 43: EQT Paid $12.1 Billion for QIAGEN, and Roche Paid $400 Million on a $15.5 Billion ADC Deal

Biotech's 2026 IPO Class Raised $6.9bn on Late-Stage Assets and Would Be $473m Under Water Without Veradermics

Biotech’s 2026 IPO Class Raised $6.9bn on Late-Stage Assets and Would Be $473m Under Water Without Veradermics

New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days

New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days

The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There

The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There

Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA

Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA

Editor’s Pick

Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS

Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

NeuroPulse

NeuroPulse Wk 43: Roche's MS Pill Cut Relapses by 55% and Is Under Priority Review

NeuroPulse Wk 43: Roche’s MS Pill Cut Relapses by 55% and Is Under Priority Review

NeuroPulse Wk 42: Arrowhead Cut Tau by 73% With a Shot Under the Skin

NeuroPulse Wk 42: Arrowhead Cut Tau by 73% With a Shot Under the Skin

OrphanPulse

OrphanPulse Wk 42: Europe Backed Ascendis' Weekly Achondroplasia Shot Ahead of the First Pill

OrphanPulse Wk 42: Europe Backed Ascendis’ Weekly Achondroplasia Shot Ahead of the First Pill

OrphanPulse Wk 41: BridgeBio Won Priority Review for the First Oral Achondroplasia Drug

OrphanPulse Wk 41: BridgeBio Won Priority Review for the First Oral Achondroplasia Drug

DealPulse Signal

DealPulse Signal Wk 43: EQT Paid $12.1 Billion for QIAGEN, and Roche Paid $400 Million on a $15.5 Billion ADC Deal

DealPulse Signal Wk 43: EQT Paid $12.1 Billion for QIAGEN, and Roche Paid $400 Million on a $15.5 Billion ADC Deal

DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Report

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats

DealPulse Signal Wk 43: EQT Paid $12.1 Billion for QIAGEN, and Roche Paid $400 Million on a $15.5 Billion ADC Deal

DealPulse Signal Wk 43: EQT Paid $12.1 Billion for QIAGEN, and Roche Paid $400 Million on a $15.5 Billion ADC Deal

DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Signal Wk 41: McKesson Bought Into Home Infusion and Shionogi Bought the Next Label

DealPulse Signal Wk 41: McKesson Bought Into Home Infusion and Shionogi Bought the Next Label

Analysis

Biotech's 2026 IPO Class Raised $6.9bn on Late-Stage Assets and Would Be $473m Under Water Without Veradermics

Biotech’s 2026 IPO Class Raised $6.9bn on Late-Stage Assets and Would Be $473m Under Water Without Veradermics

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Behind the Headlines How the Leaders Really Performed

Behind the Headlines: How the Leaders Really Performed

Coverage

ESMO 2026 Preview: Seven of Twelve Presidential Abstracts Have Already Claimed a Survival Win

ESMO 2026 Preview: Seven of Twelve Presidential Abstracts Have Already Claimed a Survival Win

ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC

The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days

New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days

Athithi Verma October 20, 2026

The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There

The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There

Athithi Verma October 20, 2026

Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA

Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA

Athithi Verma October 20, 2026

Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront

Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront

Athithi Verma October 20, 2026

The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod's Lenire a Coverage Argument

The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod’s Lenire a Coverage Argument

Athithi Verma October 19, 2026

AbbVie's Skyrizi Combination Nearly Doubled Endoscopic Remission at 24 Weeks in Crohn's, in an Open-Label Study Without Placebo

AbbVie’s Skyrizi Combination Nearly Doubled Endoscopic Remission at 24 Weeks in Crohn’s, in an Open-Label Study Without Placebo

Athithi Verma October 19, 2026

Explore Synopulse

NeuroPulse
Deals
Market Access
Industry Trends
Regulatory

About

About Synopulse
Contact Us
Announcements

© 2026 Synopulse • Built with GeneratePress